867 related articles for article (PubMed ID: 33798491)
1. Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant.
Edara VV; Norwood C; Floyd K; Lai L; Davis-Gardner ME; Hudson WH; Mantus G; Nyhoff LE; Adelman MW; Fineman R; Patel S; Byram R; Gomes DN; Michael G; Abdullahi H; Beydoun N; Panganiban B; McNair N; Hellmeister K; Pitts J; Winters J; Kleinhenz J; Usher J; O'Keefe JB; Piantadosi A; Waggoner JJ; Babiker A; Stephens DS; Anderson EJ; Edupuganti S; Rouphael N; Ahmed R; Wrammert J; Suthar MS
Cell Host Microbe; 2021 Apr; 29(4):516-521.e3. PubMed ID: 33798491
[TBL] [Abstract][Full Text] [Related]
2. B.1.526 SARS-CoV-2 Variants Identified in New York City are Neutralized by Vaccine-Elicited and Therapeutic Monoclonal Antibodies.
Zhou H; Dcosta BM; Samanovic MI; Mulligan MJ; Landau NR; Tada T
mBio; 2021 Aug; 12(4):e0138621. PubMed ID: 34311587
[TBL] [Abstract][Full Text] [Related]
3. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.
Wang P; Nair MS; Liu L; Iketani S; Luo Y; Guo Y; Wang M; Yu J; Zhang B; Kwong PD; Graham BS; Mascola JR; Chang JY; Yin MT; Sobieszczyk M; Kyratsous CA; Shapiro L; Sheng Z; Huang Y; Ho DD
Nature; 2021 May; 593(7857):130-135. PubMed ID: 33684923
[TBL] [Abstract][Full Text] [Related]
4. Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants.
Choi A; Koch M; Wu K; Dixon G; Oestreicher J; Legault H; Stewart-Jones GBE; Colpitts T; Pajon R; Bennett H; Carfi A; Edwards DK
J Virol; 2021 Nov; 95(23):e0131321. PubMed ID: 34549975
[TBL] [Abstract][Full Text] [Related]
5. Convalescent-Phase Sera and Vaccine-Elicited Antibodies Largely Maintain Neutralizing Titer against Global SARS-CoV-2 Variant Spikes.
Tada T; Dcosta BM; Samanovic MI; Herati RS; Cornelius A; Zhou H; Vaill A; Kazmierski W; Mulligan MJ; Landau NR
mBio; 2021 Jun; 12(3):e0069621. PubMed ID: 34060334
[TBL] [Abstract][Full Text] [Related]
6. Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies.
Planas D; Bruel T; Grzelak L; Guivel-Benhassine F; Staropoli I; Porrot F; Planchais C; Buchrieser J; Rajah MM; Bishop E; Albert M; Donati F; Prot M; Behillil S; Enouf V; Maquart M; Smati-Lafarge M; Varon E; Schortgen F; Yahyaoui L; Gonzalez M; De Sèze J; Péré H; Veyer D; Sève A; Simon-Lorière E; Fafi-Kremer S; Stefic K; Mouquet H; Hocqueloux L; van der Werf S; Prazuck T; Schwartz O
Nat Med; 2021 May; 27(5):917-924. PubMed ID: 33772244
[TBL] [Abstract][Full Text] [Related]
7. Long-term, infection-acquired immunity against the SARS-CoV-2 Delta variant in a hamster model.
Halfmann PJ; Kuroda M; Armbrust T; Accola M; Valdez R; Kowalski-Dobson T; Rehrauer W; Gordon A; Kawaoka Y
Cell Rep; 2022 Feb; 38(7):110394. PubMed ID: 35139368
[TBL] [Abstract][Full Text] [Related]
8. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.
Weisblum Y; Schmidt F; Zhang F; DaSilva J; Poston D; Lorenzi JC; Muecksch F; Rutkowska M; Hoffmann HH; Michailidis E; Gaebler C; Agudelo M; Cho A; Wang Z; Gazumyan A; Cipolla M; Luchsinger L; Hillyer CD; Caskey M; Robbiani DF; Rice CM; Nussenzweig MC; Hatziioannou T; Bieniasz PD
Elife; 2020 Oct; 9():. PubMed ID: 33112236
[TBL] [Abstract][Full Text] [Related]
9. The Antigenicity of Epidemic SARS-CoV-2 Variants in the United Kingdom.
Wu J; Zhang L; Zhang Y; Wang H; Ding R; Nie J; Li Q; Liu S; Yu Y; Yang X; Duan K; Qu X; Wang Y; Huang W
Front Immunol; 2021; 12():687869. PubMed ID: 34220844
[TBL] [Abstract][Full Text] [Related]
10. Reduced binding and neutralization of infection- and vaccine-induced antibodies to the B.1.351 (South African) SARS-CoV-2 variant.
Edara VV; Norwood C; Floyd K; Lai L; Davis-Gardner ME; Hudson WH; Mantus G; Nyhoff LE; Adelman MW; Fineman R; Patel S; Byram R; Gomes DN; Michael G; Abdullahi H; Beydoun N; Panganiban B; McNair N; Hellmeister K; Pitts J; Winters J; Kleinhenz J; Usher J; O'Keefe JB; Piantadosi A; Waggoner JJ; Babiker A; Stephens DS; Anderson EJ; Edupuganti S; Rouphael N; Ahmed R; Wrammert J; Suthar MS
bioRxiv; 2021 Feb; ():. PubMed ID: 33655254
[TBL] [Abstract][Full Text] [Related]
11. High-titer neutralization of Mu and C.1.2 SARS-CoV-2 variants by vaccine-elicited antibodies of previously infected individuals.
Tada T; Zhou H; Dcosta BM; Samanovic MI; Cornelius A; Herati RS; Mulligan MJ; Landau NR
Cell Rep; 2022 Jan; 38(2):110237. PubMed ID: 34982967
[TBL] [Abstract][Full Text] [Related]
12. The effect of spike mutations on SARS-CoV-2 neutralization.
Rees-Spear C; Muir L; Griffith SA; Heaney J; Aldon Y; Snitselaar JL; Thomas P; Graham C; Seow J; Lee N; Rosa A; Roustan C; Houlihan CF; Sanders RW; Gupta RK; Cherepanov P; Stauss HJ; Nastouli E; ; Doores KJ; van Gils MJ; McCoy LE
Cell Rep; 2021 Mar; 34(12):108890. PubMed ID: 33713594
[TBL] [Abstract][Full Text] [Related]
13. Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines.
Yang Y; Zang J; Xu S; Zhang X; Yuan S; Wang H; Lavillette D; Zhang C; Huang Z
Viruses; 2021 Jul; 13(8):. PubMed ID: 34452287
[TBL] [Abstract][Full Text] [Related]
14. Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine.
Melo-González F; Soto JA; González LA; Fernández J; Duarte LF; Schultz BM; Gálvez NMS; Pacheco GA; Ríos M; Vázquez Y; Rivera-Pérez D; Moreno-Tapia D; Iturriaga C; Vallejos OP; Berríos-Rojas RV; Hoppe-Elsholz G; Urzúa M; Bruneau N; Fasce RA; Mora J; Grifoni A; Sette A; Weiskopf D; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Ramírez E; Kalergis AM; Bueno SM
Front Immunol; 2021; 12():747830. PubMed ID: 34858404
[TBL] [Abstract][Full Text] [Related]
15. Pre-Omicron Vaccine Breakthrough Infection Induces Superior Cross-Neutralization against SARS-CoV-2 Omicron BA.1 Compared to Infection Alone.
da Silva ES; Kohnen M; Gilson G; Staub T; Arendt V; Hilger C; Servais JY; Charpentier E; Domingues O; Snoeck CJ; Ollert M; Seguin-Devaux C; Perez-Bercoff D
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887023
[TBL] [Abstract][Full Text] [Related]
16. Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern.
Dupont L; Snell LB; Graham C; Seow J; Merrick B; Lechmere T; Maguire TJA; Hallett SR; Pickering S; Charalampous T; Alcolea-Medina A; Huettner I; Jimenez-Guardeño JM; Acors S; Almeida N; Cox D; Dickenson RE; Galao RP; Kouphou N; Lista MJ; Ortega-Prieto AM; Wilson H; Winstone H; Fairhead C; Su JZ; Nebbia G; Batra R; Neil S; Shankar-Hari M; Edgeworth JD; Malim MH; Doores KJ
Nat Microbiol; 2021 Nov; 6(11):1433-1442. PubMed ID: 34654917
[TBL] [Abstract][Full Text] [Related]
17. High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.
Nitahara Y; Nakagama Y; Kaku N; Candray K; Michimuko Y; Tshibangu-Kabamba E; Kaneko A; Yamamoto H; Mizobata Y; Kakeya H; Yasugi M; Kido Y
Microbiol Spectr; 2021 Dec; 9(3):e0096521. PubMed ID: 34756082
[TBL] [Abstract][Full Text] [Related]
18. The mRNA-1273 Vaccine Induces Cross-Variant Antibody Responses to SARS-CoV-2 With Distinct Profiles in Individuals With or Without Pre-Existing Immunity.
Tejedor Vaquero S; de Campos-Mata L; Ramada JM; Díaz P; Navarro-Barriuso J; Ribas-Llaurado C; Rodrigo Melero N; Carolis C; Cerutti A; Gimeno R; Magri G
Front Immunol; 2021; 12():737083. PubMed ID: 34539673
[TBL] [Abstract][Full Text] [Related]
19. Steep Decline in Binding Capability of SARS-CoV-2 Omicron Variant (B.1.1.529) RBD to the Antibodies in Early COVID-19 Convalescent Sera and Inactivated Vaccine Sera.
Zhou W; He P; Li J; Liu H; Shi M; Yu J; Wei H
Viruses; 2022 Feb; 14(2):. PubMed ID: 35215927
[TBL] [Abstract][Full Text] [Related]
20. SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines.
Shen X; Tang H; McDanal C; Wagh K; Fischer W; Theiler J; Yoon H; Li D; Haynes BF; Sanders KO; Gnanakaran S; Hengartner N; Pajon R; Smith G; Glenn GM; Korber B; Montefiori DC
Cell Host Microbe; 2021 Apr; 29(4):529-539.e3. PubMed ID: 33705729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
